{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:57Z","timestamp":1777370937345,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cld.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:16:22Z","timestamp":1747034182000},"page":"483-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatotoxicity of Chemotherapy and Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"29","author":[{"given":"Peter D.","family":"Block","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Assis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0034-1375957","article-title":"Drug-induced liver injury due to cancer chemotherapeutic agents","volume":"34","author":"Bahirwani","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib4","first-page":"1194","article-title":"Immunotherapy-induced hepatotoxicity: a review","volume":"10","author":"Da","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2019.08.003","article-title":"Genetic predisposition to drug-induced liver injury","volume":"24","author":"Stephens","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib6","first-page":"95","article-title":"Hepatotoxicity secondary to chemotherapy","volume":"2","author":"Grigorian","year":"2014","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib8","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"36","key":"10.1016\/j.cld.2025.03.006_bib9","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib10","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"issue":"31","key":"10.1016\/j.cld.2025.03.006_bib11","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.cld.2025.03.006_bib12","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J Clin Cases"},{"issue":"5","key":"10.1016\/j.cld.2025.03.006_bib13","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2011.07.051","article-title":"Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury","volume":"141","author":"Davern","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.03.006_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel uclaf causality assessment method for drug-induced liver injury: present and future","volume":"10","author":"Danan","year":"2019","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.cld.2025.03.006_bib15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.cld.2025.03.006_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40264-014-0185-4","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib19","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method","volume":"51","author":"Rockey","year":"2010","journal-title":"Hepatol Baltim Md"},{"issue":"5","key":"10.1016\/j.cld.2025.03.006_bib20","first-page":"1623","article-title":"Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug-induced liver injury network (DILIN)","volume":"35","author":"Hayashi","year":"2015","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cpt.1571","article-title":"Next-generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development","volume":"107","author":"Roth","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"49","key":"10.1016\/j.cld.2025.03.006_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013478","article-title":"The diagnostic role of miR-122 in drug-induced liver injury","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine (Baltim)"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.03.006_bib23","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/cld.856","article-title":"The origins of the modern-day study of drug hepatotoxicity: focus on Hyman J. Zimmerman","volume":"15","author":"Lewis","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib24","article-title":"Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"M","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.03.006_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","article-title":"Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bonifazi","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib29","article-title":"Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Na","year":"2018","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"10.1016\/j.cld.2025.03.006_bib30","doi-asserted-by":"crossref","first-page":"e24094","DOI":"10.1200\/JCO.2023.41.16_suppl.e24094","article-title":"Non-hematopoietic cell transplant-related veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) in solid tumor and hematologic malignancies: a systematic review","volume":"41","author":"Stewart","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatol Baltim Md"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib34","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Ja","year":"2010","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2012.749855","article-title":"Drug safety evaluation of defibrotide","volume":"12","author":"Richardson","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"10.1016\/j.cld.2025.03.006_bib37","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2015-10-676114","article-title":"What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance","volume":"127","author":"Palomo","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cld.2025.03.006_bib38","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Pg","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cld.2025.03.006_bib39","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the International Compassionate-Use Program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.cld.2025.03.006_bib41","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","article-title":"Targeting metabolism for cancer therapy","volume":"24","author":"Luengo","year":"2017","journal-title":"Cell Chem Biol"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib42","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cld.2013.07.010","article-title":"Chemotherapy-induced hepatotoxicity","volume":"17","author":"Thatishetty","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2025.03.006_bib43","unstructured":"John W. Eklund MD, Mary F, et al. Chemotherapy dosing in the setting of liver dysfunction. 2005;19. Accessed October 14, 2024. Available at: https:\/\/www.cancernetwork.com\/view\/chemotherapy-dosing-setting-liver-dysfunction."},{"issue":"5","key":"10.1016\/j.cld.2025.03.006_bib44","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation","volume":"84","author":"Jh","year":"2005","journal-title":"Ann Hematol"},{"issue":"17","key":"10.1016\/j.cld.2025.03.006_bib45","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.7150\/jca.47470","article-title":"Antibiotics for cancer treatment: a double-edged sword","volume":"11","author":"Gao","year":"2020","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib46","article-title":"A clinical review of bleomycin--a new antineoplastic agent","volume":"31","author":"Rh","year":"1973","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cld.2025.03.006_bib47","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/1097-0142(19840301)53:5<1042::AID-CNCR2820530505>3.0.CO;2-B","article-title":"Acute doxorubicin toxicity relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia","volume":"53","author":"Brenner","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.cld.2025.03.006_bib48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.7150\/jca.2.527","article-title":"Dactinomycin-induced hepatic sinusoidal obstruction syndrome responding to treatment with N-acetylcysteine","volume":"2","author":"Lee","year":"2011","journal-title":"J Cancer"},{"issue":"9","key":"10.1016\/j.cld.2025.03.006_bib49","article-title":"Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment","volume":"67","author":"de L","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1097-0142(197307)32:1<38::AID-CNCR2820320105>3.0.CO;2-I","article-title":"A Haut. CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer","volume":"32","author":"Hoogstraten","year":"1973","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib51","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/1097-0142(197410)34:4<993::AID-CNCR2820340404>3.0.CO;2-T","article-title":"Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)","volume":"34","author":"Schien","year":"1974","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib52","article-title":"The effect of an individual\u2019s cytochrome CYP3A4 activity on docetaxel clearance","volume":"6","author":"J","year":"2000","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib53","article-title":"Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases","volume":"20","author":"K","year":"2014","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib54","article-title":"Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice","volume":"100","author":"H","year":"2009","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib55","article-title":"The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination","volume":"8","author":"Hw","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0009-9236(96)90021-1","article-title":"Pharmacokinetics of vinorelbine in patients with liver metastases","volume":"59","author":"Robieux","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib57","article-title":"Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan","volume":"2","author":"Rh","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0168-8278(91)90905-Q","article-title":"Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments","volume":"12","author":"Tran","year":"1991","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib60","article-title":"Toxicity of platinum compounds","volume":"4","author":"Jt","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02897264","article-title":"High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity","volume":"26","author":"Jones","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/07357909109021323","article-title":"Fatal thrombocytopenia and liver failure associated with carboplatin therapy","volume":"9","author":"Hruban","year":"1991","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2217\/pme-2016-0085","article-title":"Lethal hepatotoxicity following 5-fluorouracil\/cisplatin chemotherapy: a relevant case report","volume":"14","author":"Hajj","year":"2017","journal-title":"Pers Med"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib64","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"31","key":"10.1016\/j.cld.2025.03.006_bib65","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib66","first-page":"609","article-title":"Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases","volume":"34","author":"Morris-Stiff","year":"2008","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"12","key":"10.1016\/j.cld.2025.03.006_bib67","article-title":"Porto-sinusoidal vascular disease associated to oxaliplatin: an entity to think about it","volume":"8","author":"A","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib68","first-page":"3461","article-title":"Management of hepatotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"8","key":"10.1016\/j.cld.2025.03.006_bib69","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00228-020-02897-x","article-title":"Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study","volume":"76","author":"Han","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.cld.2025.03.006_bib70","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","article-title":"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on\/7 days off in patients with advanced, refractory solid tumours","volume":"92","author":"Awada","year":"2005","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib72","article-title":"Hepatotoxicity of small molecule protein kinase inhibitors for cancer","volume":"15","author":"M","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.cld.2025.03.006_bib73","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.03.006_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000063","article-title":"Hepatotoxicity of immune checkpoint inhibitors: what is currently known","volume":"7","author":"Zheng","year":"2023","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.cld.2025.03.006_bib77","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.cld.2025.03.006_bib78","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/cancers16112042","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma and their hepatic-related side effects: a review","volume":"16","author":"Ruli","year":"2024","journal-title":"Cancers"},{"issue":"1S Suppl 1","key":"10.1016\/j.cld.2025.03.006_bib79","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"B","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1118","key":"10.1016\/j.cld.2025.03.006_bib80","article-title":"Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography","volume":"94","author":"Ma","year":"2021","journal-title":"Br J Radiol"},{"issue":"2","key":"10.1016\/j.cld.2025.03.006_bib81","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatol Baltim Md"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib82","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.cld.2025.03.006_bib83","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.cld.2025.03.006_bib84","article-title":"Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"J","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.cld.2025.03.006_bib85","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"issue":"17","key":"10.1016\/j.cld.2025.03.006_bib86","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.cld.2025.03.006_bib87","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study","volume":"21","author":"Riveiro-Barciela","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.03.006_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.cld.2025.03.006_bib89","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000525","article-title":"Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis","volume":"8","author":"Hwang","year":"2024","journal-title":"Hepatol Commun"},{"issue":"7","key":"10.1016\/j.cld.2025.03.006_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008074","article-title":"Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids","volume":"12","author":"Burri","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:30:42Z","timestamp":1752676242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1089326125000224"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.03.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatotoxicity of Chemotherapy and Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}